Abstract
ObjectivesTo present analysis of pooled data through approx 3yrs of follow-up from 5 ongoing golimumab (GLM) Ph3 SC trials across rheumatological indications and through 1yr in a completed Ph2 RA...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have